IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Overview
Iovance Biotherapeutics develops and commercializes tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers.
IOVANCE BIOTHERAPEUTICS, INC is a Healthcare company operating in Biotechnology with a $1.75B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-077 Q&A exchanges
- Q4 FY2025Earnings2026-02-2414 Q&A exchanges
- Q3 FY2025Earnings2025-11-068 Q&A exchanges
- Q2 FY2025Earnings2025-08-0812 Q&A exchanges
- Q1 FY2025Earnings2025-05-0818 Q&A exchanges
- Q4 FY2024Earnings2025-02-2722 Q&A exchanges
- Q3 FY2024Earnings2024-11-0715 Q&A exchanges
- Q2 FY2024Earnings2024-08-0824 Q&A exchanges
- Q1 FY2024Earnings2024-05-0921 Q&A exchanges
- Q4 FY2023Earnings2024-02-2837 Q&A exchanges
- Q3 FY2023Earnings2023-11-0719 Q&A exchanges
- Q2 FY2023Earnings2023-08-0840 Q&A exchanges
- Q1 FY2023Earnings2023-05-0925 Q&A exchanges
- Q4 FY2022Earnings2023-03-0129 Q&A exchanges
- Q3 FY2022Earnings2022-11-0327 Q&A exchanges
- Q2 FY2022Earnings2022-08-0435 Q&A exchanges
- Q1 FY2022Earnings2022-05-0528 Q&A exchanges
- Q4 FY2021Earnings2022-02-2434 Q&A exchanges
- Q3 FY2021Earnings2021-11-0528 Q&A exchanges
- Q2 FY2021Earnings2021-08-0523 Q&A exchanges
- Q1 FY2021Earnings2021-05-0614 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $-0.17—Rev— vs ——EODHD
- Q1 FY20262026-03-30EPS$-0.19 vs $-0.15-23.8%Rev$71.4M vs ——EODHD
- Q4 FY20252025-12-30EPS$-0.18 vs $-0.18-2.0%Rev$86.8M vs ——EODHD
- Q3 FY20252025-11-05EPS$-0.25 vs $-0.26+4.5%Rev$67.5M vs ——EODHD
- Q2 FY20252025-08-06EPS$-0.33 vs $-0.28-17.9%Rev$60.0M vs ——EODHD
- Q1 FY20252025-05-06EPS$-0.36 vs $-0.42+14.3%Rev$49.3M vs ——EODHD
- Q4 FY20242025-02-25EPS$-0.26 vs $-0.27+2.8%Rev$73.7M vs ——EODHD
- Q3 FY20242024-11-06EPS$-0.28 vs $-0.30+6.7%Rev$58.6M vs ——EODHD
- Q2 FY20242024-08-07EPS$-0.34 vs $-0.35+2.9%Rev$31.1M vs ——EODHD
- Q1 FY20242024-05-08EPS$-0.42 vs $-0.420.0%Rev$715.0K vs ——EODHD
- Q4 FY20232024-02-27EPS$-0.45 vs $-0.43-4.7%Rev$482.0K vs ——EODHD
- Q3 FY20232023-11-06EPS$-0.46 vs $-0.45-2.2%Rev$469.0K vs ——EODHD
- Q2 FY20232023-08-07EPS$-0.47 vs $-0.80+41.3%Rev$238.0K vs ——EODHD
- Q1 FY20232023-05-08EPS$-0.50 vs $-0.74+32.4%Rev$0 vs ——EODHD
- Q4 FY20222023-02-27EPS$-0.64 vs $-0.640.0%Rev$0 vs ——EODHD
- Q3 FY20222022-11-02EPS$-0.63 vs $-0.64+1.6%Rev$0 vs ——EODHD
- Q2 FY20222022-08-03EPS$-0.63 vs $-0.61-3.3%Rev$0 vs ——EODHD
- Q1 FY20222022-05-04EPS$-0.58 vs $-0.64+9.4%Rev$0 vs ——EODHD
- Q4 FY20212022-02-23EPS$-0.63 vs $-0.56-12.5%Rev$0 vs ——EODHD
- Q3 FY20212021-11-03EPS$-0.55 vs $-0.53-3.8%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $-0.17 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-03-30 | $-0.19 | $-0.15 | -23.8% | $71.4M | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-0.18 | $-0.18 | -2.0% | $86.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.25 | $-0.26 | +4.5% | $67.5M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.33 | $-0.28 | -17.9% | $60.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.36 | $-0.42 | +14.3% | $49.3M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.26 | $-0.27 | +2.8% | $73.7M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.28 | $-0.30 | +6.7% | $58.6M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.34 | $-0.35 | +2.9% | $31.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.42 | $-0.42 | 0.0% | $715.0K | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $-0.45 | $-0.43 | -4.7% | $482.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.46 | $-0.45 | -2.2% | $469.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.47 | $-0.80 | +41.3% | $238.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $-0.50 | $-0.74 | +32.4% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-0.64 | $-0.64 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.63 | $-0.64 | +1.6% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.63 | $-0.61 | -3.3% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.58 | $-0.64 | +9.4% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $-0.63 | $-0.56 | -12.5% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.55 | $-0.53 | -3.8% | $0 | — | — | EODHD |
Source: EODHD. IOVA reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks IOVA's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.57 | $3.26 | -21.3% | -3.9% | -4.9% |
| Q4 FY2026 | $2.60 | $3.25 | -20.0% | +2.2% | +4.4% |
| Q3 FY2026 | $3.03 | $3.36 | -9.9% | -2.8% | -5.0% |
| Q2 FY2026 | $2.86 | $3.42 | -16.5% | +3.2% | +4.8% |
| Q1 FY2025 | $2.78 | $3.45 | -19.4% | -5.5% | -4.1% |
| Q4 FY2025 | $3.00 | $3.44 | -12.7% | -5.2% | -2.3% |
| Q3 FY2025 | $3.09 | $3.58 | -13.8% | -2.2% | -2.2% |
| Q2 FY2025 | $3.23 | $3.47 | -6.8% | +1.9% | +2.6% |
| Q1 FY2024 | $2.79 | $3.60 | -22.4% | -4.5% | -3.3% |
| Q4 FY2024 | $2.70 | $3.38 | -20.2% | -8.3% | -10.2% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Frederick G VogtCEO1 yr 1 mo19 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
- Corleen M RocheCFO10 mo3 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
- Jean-marc BelleminCFO1 yr17 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last call held guidance Q3 FY2026
- Igor BilinskyCOO1 yr18 callsCurrentSample
COO since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Daniel Gordon KirbyChief Commercial Officer1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Finckenstein Friedrich GrafChief Medical Officer1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/4 beats (25%) • last guidance raise Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IOVA.
$ curl https://api.spokenalpha.com/v1/companies/IOVAFAQ
Frequently asked about IOVA
Where can I find IOVANCE BIOTHERAPEUTICS, INC.'s (IOVA) earnings call transcripts?
Spoken Alpha indexes IOVA's earnings call transcripts at https://spokenalpha.com/companies/IOVA. Each call links to attributed speakers and parsed analyst Q&A.
When was IOVANCE BIOTHERAPEUTICS, INC.'s most recent earnings call?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is IOVA in?
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) operates in the Healthcare sector (Biotechnology industry).